|
|
News Breaks
|
November 19, 2009
|
| 06:31 EDT |  | XNPT |
| theflyonthewall.com: | XenoPort, Astellas announce submission of NDA in Japan | | Astellas Pharma and XenoPort announced that a new drug application has been filed with the Pharmaceuticals and Medical Device Agency in Japan for ASP8825, also known as XP13512, as a potential treatment for restless legs syndrome. The data supporting safety and efficacy in the NDA filing comes from the successful Phase 2 study in RLS patients and long-term safety study conducted by Astellas in Japan and the RLS clinical program conducted by XenoPort in the United States. The acceptance of filing of the NDA triggers a $5 million milestone payment from Astellas to XenoPort. :theflyonthewall.com |
|
|
News For XNPT From The Last 14 Days Check below for free stories on XNPT the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
January 31, 2012
|
| 11:21 EDT |  | XNPT |
|
|
|
|
|
Subscribe for More Information